Genmab (OTC) Maps Catalyst-Rich Path After Strong Q1

Genmab (Otc) ((GMAB)) has held its Q1 earnings call. Read on for the main highlights of the call.

Genmab’s latest earnings call painted a picture of a company balancing strong commercial execution with heavy investment in its pipeline. Management emphasized robust top-line growth, widening operating margins and a 2026 calendar dense with pivotal readouts, while openly flagging tax volatility, elevated spending and binary trial risk. Overall tone skewed confident, with positives seen as outweighing the clear, if manageable, uncertainties.

Total Revenue Growth

Genmab reported a 25% year-over-year rise in total revenue for Q1 2026, underpinned by a more diversified mix of income streams. Royalty flows from partnered blockbusters like DARZALEX and Kesimpta combined with accelerating sales from the company’s own medicines, underscoring the shift from a pure royalty player to a broader commercial biopharma.

Proprietary Portfolio Sales Momentum

Proprietary product sales climbed to $176 million in the quarter, a 43% increase versus the prior year. The surge reflects strong uptake of EPKINLY and Tivdak both in established regions and new markets, suggesting Genmab’s in-house portfolio is becoming a more meaningful driver of growth and helping reduce reliance on partner royalties.

EPKINLY Commercial Performance and Label Update

EPKINLY delivered $137 million in Q1 sales, up 52% year-over-year, cementing its status as Genmab’s key growth engine. Management highlighted a fixed-duration approval with R2 in second-line follicular lymphoma, broad approvals across more than 65 countries and an important U.S. label change removing a 24-hour hospitalization recommendation, which should expand outpatient and community usage.

Tivdak Growth and Geographic Expansion

Tivdak generated $39 million in Q1, an 18% year-over-year increase, as it maintained leadership in recurrent or metastatic cervical cancer in the U.S. The company is now pushing Tivdak into Japan, Europe and the U.K., where direct commercialization and health-technology assessments are underway, providing additional runway for incremental revenue and geographic diversification.

Profitability While Investing in Growth

Despite ramped investment in late-stage programs and launch preparation, Genmab grew operating profit by 23% in Q1, signaling improving operating leverage. The company reaffirmed 2026 guidance with a midpoint of roughly 14% revenue growth and operating expenses of about $2.7–$2.9 billion, underscoring its willingness to spend aggressively while still targeting expanding profitability.

Rina-S Development Acceleration and Milestones

The Rina-S program advanced significantly, with the Phase III RAINFOL-02 trial in second-line plus platinum-resistant ovarian cancer completing enrollment earlier than expected, pulling pivotal data into 2026. Two additional Phase III trials, including a chemo-replacement study in platinum-sensitive ovarian cancer and a first-line endometrial cancer trial, are slated to start soon, with two Rina-S datasets in H2 2026 supporting possible 2027 launches.

Petosemtamab Progress and Merus Integration

Development of petosemtamab remains on track, with one or more clinical readouts expected this year as Genmab integrates Merus to capture full asset value. While acquisition-related costs and amortization are excluded from the reported numbers and discussed in reconciliations, management framed the integration as a strategic move to bolster Genmab’s late-stage oncology portfolio.

Clinical Execution and Faster Enrollment

Management underscored strong clinical execution, noting several key trials have enrolled patients faster than projected, including RAINFOL-02 and multiple EPKINLY studies. This acceleration brings forward expected readouts, creating a 2026 calendar packed with potential catalysts that, if positive, could underpin multiple commercial launches in 2027.

Tax Rate Volatility from Merus Integration

Genmab recorded roughly $21 million in tax expense in Q1, translating to an effective tax rate of 28.9%. However, executives cautioned that the ongoing Merus integration could trigger swings in the effective tax rate over the next 12–18 months, adding noise to after-tax earnings until the structure stabilizes.

Large Planned Operating Investment

The company flagged significant operating investment for 2026, with projected expenses of $2.7–$2.9 billion to fund late-stage development of petosemtamab and Rina-S and to prepare for potential launches. This marks a material step-up in spending, and management acknowledged investors should closely track whether revenue and future approvals justify the heavier cost base.

Competitive Pressure in Rina-S Target Space

Rina-S, a B7-H4 antibody-drug conjugate, will face intense competition from other B7-H4 programs, including those from major and emerging players. While Genmab expressed confidence in its data package and speed to market, it acknowledged that the crowded field could influence ultimate market share and pricing dynamics once multiple agents reach the clinic.

Trial Amendments and Limited Disclosure

The frontline petosemtamab trial was expanded from roughly 500 to 700 patients and underwent other protocol changes aimed at boosting the probability of success. Management declined to disclose detailed public information on elements like enrollment mix and statistical tweaks, insisting timelines remain intact but leaving some uncertainty around how these changes may affect trial readouts.

Dependence on Upcoming Readouts

Genmab’s medium-term outlook hinges heavily on a cluster of near-term clinical results, including EPKINLY in frontline DLBCL, multiple petosemtamab trials and Rina-S datasets in the second half. The company acknowledged that these events carry binary risk, and disappointing data or regulatory feedback could materially alter 2026–2027 commercialization plans and investor sentiment.

Revenue Guidance vs. Q1 Outperformance

While Q1 revenue grew 25%, the full-year 2026 midpoint implies about 14% growth, suggesting either a conservative outlook or an expectation of slower momentum later in the year. Investors will be watching whether current double-digit growth in proprietary products can be sustained, or if royalty dynamics and launch trajectories temper the pace as the year progresses.

Unspecified Impact of Acquisition-Related Expenses

Genmab’s reported results and guidance exclude acquisition-related costs, including amortization, which are detailed separately but not embedded in the main earnings figures. This approach supports a cleaner look at underlying operations but also introduces some opacity around full GAAP profitability and cash outflows tied to recent M&A activity.

Forward-Looking Guidance and Capital Priorities

Looking ahead, Genmab reiterated its 2026 outlook for roughly 14% revenue growth at the midpoint, with operating expenses in the $2.7–$2.9 billion range to support Rina-S, petosemtamab and launch readiness. Management reaffirmed timelines for key data readouts, including two Rina-S datasets in the second half, and reiterated its aim to reduce gross leverage below 3 times by the end of 2027, framing the period as investment-heavy but opportunity-rich.

Genmab’s earnings call underscored a company entering a pivotal stretch, pairing robust revenue and profit growth with sizeable late-stage risk and spending. For investors, the story now turns on execution: sustaining commercial momentum, navigating tax and cost volatility and, above all, delivering positive data from EPKINLY, Rina-S and petosemtamab that can justify today’s heightened investment and set up the next wave of growth.